Literature DB >> 21844184

Cyclin D1 and cdk4 mediate development of neurologically destructive oligodendroglioma.

Daniel Ciznadija1, Yuhui Liu, Stephanie M Pyonteck, Eric C Holland, Andrew Koff.   

Abstract

Although the molecular changes that characterize gliomas have been studied, the pathogenesis of tumor development remains unclear. p21 contributes to gliomagenesis by stabilizing cyclin D1-cdk4 kinase complexes, suggesting that cyclin D1 and cdk4 may also be required for glial tumor development. In this study, we used a mouse model to attempt to confirm this hypothesis, finding that cyclin D1 and cdk4 played active roles in not only the tumor but also the tumor microenvironment. Loss of cdk4 blocked tumor development, but loss of cyclin D1 did not prevent gliomas from developing. Instead, loss of cyclin D1 impeded progression to higher stages of malignancy. Enforcing expression of cyclin D1 was insufficient to correct the progression defect observed in cyclin D1-deficient animals. In contrast, restoration of cdk4 in the cdk4-deficient animals restored cell proliferation and tumor formation, although at lower tumor grades. Notably, the failure of tumors in the cyclin D1- and cdk4-deficient animals to progress to higher grades was correlated with a failure to fully activate microglia in the tumor microenvironment. Moreover, when platelet-derived growth factor-transformed glial cells were engrafted orthotopically into the mice, the tumors that formed progressed to high grades in wild-type mice but not cyclin D1-deficient animals. Together, our findings establish that the cyclin D1-cdk4 axis is not only critical in glial tumor cells but also in stromal-derived cells in the surrounding tumor microenvironment that are vital to sustain tumor outgrowth.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21844184      PMCID: PMC3185142          DOI: 10.1158/0008-5472.CAN-11-1031

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  53 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM.

Authors:  W Ruprecht Wiedemeyer; Ian F Dunn; Steven N Quayle; Jianhua Zhang; Milan G Chheda; Gavin P Dunn; Li Zhuang; Joseph Rosenbluh; Shujuan Chen; Yonghong Xiao; Geoffrey I Shapiro; William C Hahn; Lynda Chin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

3.  Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.

Authors:  Karine Michaud; David A Solomon; Eric Oermann; Jung-Sik Kim; Wei-Zhu Zhong; Michael D Prados; Tomoko Ozawa; C David James; Todd Waldman
Journal:  Cancer Res       Date:  2010-03-30       Impact factor: 12.701

4.  Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway.

Authors:  J A Diehl; F Zindy; C J Sherr
Journal:  Genes Dev       Date:  1997-04-15       Impact factor: 11.361

Review 5.  Microglial action in glioma: a boon turns bane.

Authors:  Anirban Ghosh; Swapna Chaudhuri
Journal:  Immunol Lett       Date:  2010-03-23       Impact factor: 3.685

6.  Glioma cancer stem cells induce immunosuppressive macrophages/microglia.

Authors:  Adam Wu; Jun Wei; Ling-Yuan Kong; Yongtao Wang; Waldemar Priebe; Wei Qiao; Raymond Sawaya; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2010-07-28       Impact factor: 12.300

7.  IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion.

Authors:  Vasilena Gocheva; Hao-Wei Wang; Bedrick B Gadea; Tanaya Shree; Karen E Hunter; Alfred L Garfall; Tara Berman; Johanna A Joyce
Journal:  Genes Dev       Date:  2010-01-15       Impact factor: 11.361

8.  Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion.

Authors:  D S Markovic; K Vinnakota; S Chirasani; M Synowitz; H Raguet; K Stock; M Sliwa; S Lehmann; R Kälin; N van Rooijen; K Holmbeck; F L Heppner; J Kiwit; V Matyash; S Lehnardt; B Kaminska; R Glass; H Kettenmann
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-15       Impact factor: 11.205

9.  Assessment of tumor angiogenesis as a prognostic factor of survival in patients with oligodendroglioma.

Authors:  H Quon; A Hasbini; J Cougnard; L Djafari; C Lacroix; B Abdulkarim
Journal:  J Neurooncol       Date:  2009-07-19       Impact factor: 4.130

10.  Defective DNA double-strand break repair underlies enhanced tumorigenesis and chromosomal instability in p27-deficient mice with growth factor-induced oligodendrogliomas.

Authors:  W L See; J P Miller; M Squatrito; E Holland; M D Resh; A Koff
Journal:  Oncogene       Date:  2010-01-11       Impact factor: 9.867

View more
  21 in total

Review 1.  CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought.

Authors:  Mary E Klein; Marta Kovatcheva; Lara E Davis; William D Tap; Andrew Koff
Journal:  Cancer Cell       Date:  2018-05-03       Impact factor: 31.743

2.  The CDK6-c-Jun-Sp1-MMP-2 axis as a biomarker and therapeutic target for triple-negative breast cancer.

Authors:  Chi-Wen Luo; Ming-Feng Hou; Chia-Wei Huang; Chun-Chieh Wu; Fu Ou-Yang; Qiao-Lin Li; Cheng-Che Wu; Mei-Ren Pan
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

3.  Wnt-mediated endothelial transformation into mesenchymal stem cell-like cells induces chemoresistance in glioblastoma.

Authors:  Menggui Huang; Duo Zhang; Janet Y Wu; Kun Xing; Eujin Yeo; Chunsheng Li; Lin Zhang; Eric Holland; Lutian Yao; Ling Qin; Zev A Binder; Donald M O'Rourke; Steven Brem; Constantinos Koumenis; Yanqing Gong; Yi Fan
Journal:  Sci Transl Med       Date:  2020-02-26       Impact factor: 17.956

Review 4.  Cell cycle proteins as promising targets in cancer therapy.

Authors:  Tobias Otto; Piotr Sicinski
Journal:  Nat Rev Cancer       Date:  2017-01-27       Impact factor: 60.716

5.  Tyrosine phosphorylation of the p21 cyclin-dependent kinase inhibitor facilitates the development of proneural glioma.

Authors:  Ellen Hukkelhoven; Yuhui Liu; Nancy Yeh; Daniel Ciznadija; Stacy W Blain; Andrew Koff
Journal:  J Biol Chem       Date:  2012-09-24       Impact factor: 5.157

6.  miR-124 radiosensitizes human glioma cells by targeting CDK4.

Authors:  Xubin Deng; Lei Ma; Minhua Wu; Gong Zhang; Chuan Jin; Yuping Guo; Ruilei Liu
Journal:  J Neurooncol       Date:  2013-06-13       Impact factor: 4.130

7.  Cyclin d1 downregulation contributes to anticancer effect of isorhapontigenin on human bladder cancer cells.

Authors:  Yong Fang; Zipeng Cao; Qi Hou; Chen Ma; Chunsuo Yao; Jingxia Li; Xue-Ru Wu; Chuanshu Huang
Journal:  Mol Cancer Ther       Date:  2013-05-30       Impact factor: 6.261

8.  Temporal DNA-PK activation drives genomic instability and therapy resistance in glioma stem cells.

Authors:  Yanling Wang; Haineng Xu; Tianrun Liu; Menggui Huang; Param-Puneet Butter; Chunsheng Li; Lin Zhang; Gary D Kao; Yanqing Gong; Amit Maity; Constantinos Koumenis; Yi Fan
Journal:  JCI Insight       Date:  2018-02-08

9.  c-Met-mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma.

Authors:  Menggui Huang; Tianrun Liu; Peihong Ma; R Alan Mitteer; Zhenting Zhang; Hyun Jun Kim; Eujin Yeo; Duo Zhang; Peiqiang Cai; Chunsheng Li; Lin Zhang; Botao Zhao; Laura Roccograndi; Donald M O'Rourke; Nadia Dahmane; Yanqing Gong; Constantinos Koumenis; Yi Fan
Journal:  J Clin Invest       Date:  2016-04-04       Impact factor: 14.808

10.  NOTCH3 is a prognostic factor that promotes glioma cell proliferation, migration and invasion via activation of CCND1 and EGFR.

Authors:  Mohammad A Y Alqudah; Supreet Agarwal; Maha S Al-Keilani; Zita A Sibenaller; Timothy C Ryken; Mahfoud Assem
Journal:  PLoS One       Date:  2013-10-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.